DALLAS and FORT WORTH, Texas, May 31, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a
pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its
proprietary modified-release drug delivery technologies, today announced that Vipin K. Garg, Ph.D., President and CEO will present
at two upcoming conferences in June.
- Corporate overview at the Jefferies 2018 Healthcare Conference on Wednesday, June 6, 2018 at 8:30 a.m. ET in New York,
NY.
- Fireside chat at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018 at 1:00 p.m. ET in New York,
NY.
A live webcast of these presentations will be available on the Investor Relations page of the company’s website
at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products
utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine)
extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT®
(methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine)
extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the
first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and markets
its generic version of the branded product Tussionex®1, an extended-release oral suspension of hydrocodone and
chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold (see Full Prescribing Information, including Boxed WARNING). Additional information about Neos is
available at www.neostx.com.
1Tussionex® is a registered trademark of the UCB Group of Companies.
CONTACTS:
Richard I. Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
![Primary Logo](https://resource.globenewswire.com/Resource/Download/f2ff2f0a-adaf-45b6-8260-69343b572ad1?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2MzkjNzI5Njc4Mw==)